Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ritodrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.97 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.97 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.94 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.94 |
| ▸ | GALR3 | O60755 | 1/20 | 0.94 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ritodrine SCHEMBL3677545 | 0.98 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Rel-Ritodrine SCHEMBL3677546 | 0.98 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL122631 | 0.98 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL18952960 | 0.98 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL3677547 | 0.98 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL4430018 | 0.97 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL16267904 | 0.97 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL29395182 | 0.97 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL34194 | 0.97 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Rel-Ritodrine SCHEMBL12959065 | 0.97 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123539-A1 | METHODS FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2013-05-16 | — | — | US | claimed |
| EP-2563757-A2 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | Lundbeck Pharmaceuticals Italy S.p.A. (IT) | 2013-03-06 | — | — | EP | claimed |
| WO-2011134724-A2 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2011-11-03 | — | — | WO | claimed |
| EP-2563757-B1 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S P A (IT) | 2016-11-16 | — | — | EP | disclosed |
| US-8912360-B2 | Methods for preparing ritodrine hydrochloride | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2014-12-16 | — | — | US | disclosed |
| US-20130123539-A1 | METHODS FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2013-05-16 | — | — | US | disclosed |
| EP-2563757-A2 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | Lundbeck Pharmaceuticals Italy S.p.A. (IT) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134724-A2 | METHOD FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123539-A1 | METHODS FOR PREPARING RITODRINE HYDROCHLORIDE | COMT, ADRA2C, ADRA1D | ADRB2 76/4885LMNA 1174/4885SLC6A2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.